Doravirine Exposure and HIV-1 Suppression after Switching from an Efavirenz-Based Regimen to Doravirine-Lamivudine-Tenofovir Disoproxil Fumarate

被引：3
|
作者：
Greaves, Wayne [1 ]
Wan, Hong [2 ]
Yee, Ka Lai [3 ]
Kandala, Bhargava [3 ]
Vaddady, Pavan [3 ]
Hwang, Carey [1 ]
机构：
[1] Merck & Co Inc, Global Clin Dev Infect Dis, Kenilworth, NJ 07033 USA
[2] Merck & Co Inc, Biostat & Res Decis Sci, Kenilworth, NJ USA
[3] Merck & Co Inc, Pharmacokinet Pharmacodynam & Drug Metab, Kenilworth, NJ USA
来源：
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2019年 / 63卷 / 12期
关键词：
HIV-1; doravirine; efavirenz; efficacy; pharmacokinetics;
D O I：
10.1128/AAC.01298-19
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
Doravirine is a nonnucleoside reverse transcriptase inhibitor that has been approved for the treatment of HIV-1. In a phase 1 trial, doravirine exposure was transiently decreased when treatment was started immediately after the cessation of efavirenz treatment. In a post hoc subgroup analysis of participants who switched from an efavirenz-based regimen to doravirine-lamivudine-tenofovir disoproxil fumarate in the phase 3 DRIVE-SHIFT trial, doravirine plasma levels at week 4 were similar to noninduced levels, and HIV-1 suppression was maintained at weeks 24 and 48.
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A Phase IV Study on Safety, Tolerability and Efficacy of Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate in Treatment Naive Adult Indian Patients Living with HIV-1
    Dravid, Ameet
    Morkar, Dnyanesh
    Prasad, Dwijendra
    Ramapuram, John T.
    Patel, Kartik Vikrambhai
    Naik, K. Sunil
    Bhrusundi, Milind
    Kulkarni, Milind
    Hegde, Sanjeev
    Anuradha, S.
    Nageswaramma, Siddabathuni
    Madan, Surabhi
    Jayaprakash, Thammisetty
    Kulkarni, Vinay
    PRAGMATIC AND OBSERVATIONAL RESEARCH, 2022, 13 : 75 - 84
  • [32] Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1 infection: a guide to its use in the EU
    Deeks E.D.
    Drugs & Therapy Perspectives, 2015, 31 (8) : 251 - 258
  • [33] Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen
    Griesel, Rulan
    Banda, Clifford G.
    Zhao, Ying
    Omar, Zaayid
    Wiesner, Lubbe
    Meintjes, Graeme
    Sinxadi, Phumla
    Maartens, Gary
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 96 (01) : 85 - 91
  • [34] Efficacy and Safety 48 Weeks after Switching from Efavirenz to Rilpivirine Using Emtricitabine/Tenofovir Disoproxil Fumarate-Based Single-Tablet Regimens
    Mills, Anthony M.
    Cohen, Calvin
    DeJesus, Edwin
    Brinson, Cynthia
    Williams, Scott
    Yale, Kitty L.
    Ramanathan, Srini
    Wang, Maggie H.
    White, Kirsten
    Chuck, Susan K.
    Cheng, Andrew K.
    HIV CLINICAL TRIALS, 2013, 14 (05): : 216 - 223
  • [35] Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study
    Mills, Anthony
    Crofoot, Gordon, Jr.
    McDonald, Cheryl
    Shalit, Peter
    Flamm, Jason A.
    Gathe, Joseph, Jr.
    Scribner, Anita
    Shamblaw, David
    Saag, Michael
    Cao, Huyen
    Martin, Hal
    Das, Moupali
    Thomas, Anne
    Liu, Hui C.
    Yan, Mingjin
    Callebaut, Christian
    Custodio, Joseph
    Cheng, Andrew
    McCallister, Scott
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2015, 69 (04) : 439 - 445
  • [36] Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1-Infected Subjects: 48 Weeks Data
    Mills, A.
    Crofoot, G.
    Ortiz, R.
    Rashbaum, B.
    Towner, W.
    Ward, D.
    Brinson, C.
    Kulkarni, R.
    Garner, W.
    Ebrahimi, R.
    Cao, H.
    Cheng, A.
    Szwarcberg, J.
    HIV CLINICAL TRIALS, 2014, 15 (02): : 51 - 56
  • [37] Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study
    DeJesus, Edwin
    Ramgopal, Moti
    Crofoot, Gordon
    Ruane, Peter
    LaMarca, Anthony
    Mills, Anthony
    Martorell, Claudia T.
    de Wet, Joseph
    Stellbrink, Hans-Jurgen
    Molina, Jean-Michel
    Post, Frank A.
    Valero, Ignacio Perez
    Porter, Danielle
    Liu, Yapei
    Cheng, Andrew
    Quirk, Erin
    SenGupta, Devi
    Cao, Huyen
    LANCET HIV, 2017, 4 (05): : E205 - E213
  • [38] Efficacy and effect on lipid profiles of switching to ainuovirine-based regimen versus continuing efavirenz-based regimen in people with HIV-1: 24-week results from a real-world, retrospective, multi-center cohort study
    Wang, Chunmei
    Yu, Xiaoli
    Ke, Yingchun
    Fu, Yanhua
    Luo, Yanhe
    Li, Ying
    Bi, Yanmei
    Chen, Xingqiong
    Li, Linghua
    Zhao, Xiuhong
    Chen, Zhong
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2024, 68 (04)
  • [39] Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate
    McColl, DJ
    Margot, NA
    Wulfsohn, M
    Coakley, DF
    Cheng, AK
    Miller, MD
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (03) : 1340 - 1350
  • [40] Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate
    Menezes, Prema
    Mollan, Katie
    Hoffman, Erin
    Xie, Zimeng
    Wills, Jennifer
    Marcus, Cheryl
    Rublein, John
    Hudgens, Michael
    Eron, Joseph J., Jr.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (06) : 481 - 485
12345